NEW! Investment Companies Centre

AstraZeneca (AZN)

Sector:

Pharmaceuticals & Biotechnology

Index:

FTSE 100

Market Cap

£32,471m

Change Today

Price Down-214.00p ()

Share Price

2,245.00p

Broker snap: Merrill sees short term gains at AstraZeneca

Date: Tuesday 05 Aug 2008

LONDON (ShareCast) - Merrill Lynch has raised its rating on the drug group AstraZeneca to ‘neutral’ from ‘underperform’ and raised its target price on the stock to 2,600p from 1,900p.

While the broker has concerns in the long-term over patent expiries and pipeline risks, it does not think these will offset earnings momentum and other positive factors in the short term.

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

 

AstraZeneca Market Data

Currency UK Pounds
Share Price 2,245.00p Price Down
Change Today -214.00p
52 Week High 2,888.00
52 Week Low 1,748.00
Volume 13,856,658
Shares Issued 1,446.36m
Market Cap £32,471m
Beta 0.67
RiskGrade 287

Performance Indicators

Compare performance with the sector and the market.
Find out more
Key: vs Market vs Sector
Value
71.44% below the market average71.44% below the market average71.44% below the market average71.44% below the market average71.44% below the market average
35.06% above the sector average35.06% above the sector average35.06% above the sector average35.06% above the sector average35.06% above the sector average
Price Trend
77.76% above the market average77.76% above the market average77.76% above the market average77.76% above the market average77.76% above the market average
74.71% above the sector average74.71% above the sector average74.71% above the sector average74.71% above the sector average74.71% above the sector average
Income
3.59% below the market average3.59% below the market average3.59% below the market average3.59% below the market average3.59% below the market average
81.82% above the sector average81.82% above the sector average81.82% above the sector average81.82% above the sector average81.82% above the sector average
Growth
45.97% below the market average45.97% below the market average45.97% below the market average45.97% below the market average45.97% below the market average
63.38% below the sector average63.38% below the sector average63.38% below the sector average63.38% below the sector average63.38% below the sector average
Price Chg 6m
78.87% above the market average78.87% above the market average78.87% above the market average78.87% above the market average78.87% above the market average
75.00% above the sector average75.00% above the sector average75.00% above the sector average75.00% above the sector average75.00% above the sector average
P/E
10.34% below the market average10.34% below the market average10.34% below the market average10.34% below the market average10.34% below the market average
36.84% above the sector average36.84% above the sector average36.84% above the sector average36.84% above the sector average36.84% above the sector average
PEG Not Available
Dividend Yield
3.15% above the market average3.15% above the market average3.15% above the market average3.15% above the market average3.15% above the market average
100.00% above the sector average100.00% above the sector average100.00% above the sector average100.00% above the sector average100.00% above the sector average
EPS Growth
49.27% below the market average49.27% below the market average49.27% below the market average49.27% below the market average49.27% below the market average
69.23% below the sector average69.23% below the sector average69.23% below the sector average69.23% below the sector average69.23% below the sector average
Operating Margin
53.76% above the market average53.76% above the market average53.76% above the market average53.76% above the market average53.76% above the market average
94.59% above the sector average94.59% above the sector average94.59% above the sector average94.59% above the sector average94.59% above the sector average

What The Brokers Say

Strong Buy 14
Buy 4
Neutral 14
Sell 3
Strong Sell 2
Total 37
buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

AstraZeneca Dividends

  Latest Previous
  Interim Final
Ex-Div 06-Aug-08 06-Feb-08
Paid 15-Sep-08 17-Mar-08
Amount 55.00¢ 135.00¢

Trades for --2008

Time Volume / Share Price
0 @ 0.000p

AstraZeneca Key Personnel

CEO David R Brennan
CFO Simon Lowth

Digital Look have been voted
"Best Research and Information Provider"

4th Floor, Bankside House, 107 Leadenhall Street, London EC3A 4AF.
Registered in England and Wales (registered no. 3678570).